# BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

> **NCT06761911** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Xiuhua Sun** · enrollment: 100 (estimated)

## Conditions studied

- Hodgkin Lymphoma (Category)

## Interventions

- **DRUG:** Brentuximab Vedotin (Bv)
- **DRUG:** Sintilimab
- **DRUG:** Tislelizumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06761911
- **Lead sponsor:** Xiuhua Sun
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2025-12-17
- **Final completion:** 2026-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761911, "BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06761911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*